Bracco Imaging has received Health Canada approval for Vueway injection (gadopiclenol), a macrocyclic gadolinium-based contrast agent (GBCA), for use in contrast-enhanced MRI.
Vueway is indicated for adults and children two years and older to detect and visualize lesions in the central nervous system -- including the brain, spine, and surrounding tissues -- as well as the body, including the head and neck, thorax, abdomen, pelvis, and musculoskeletal system, according to the company.
Bracco highlighted contrast enhancement and reduced gadolinium exposure at a dose of 0.05 mmol/kg. According to the company, Vueway has the highest longitudinal relaxivity values among macrocyclic GBCAs approved in major global markets.
The Health Canada approval follows clearances in the U.S. (2022) and European Union (2023). Vueway is now approved in 37 countries, with more than 4 million patient doses administered worldwide, Bracco noted.
